Search

Your search keyword '"Yamaguchi, Kensei"' showing total 454 results
Start Over Author "Yamaguchi, Kensei" Database Unpaywall
454 results on '"Yamaguchi, Kensei"'

1. Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis

Author

Kang, Yoon-Koo, primary, Qin, Shukui, additional, Lee, Keun-Wook, additional, Oh, Sang Cheul, additional, Kim, In-Ho, additional, Kim, Jong Gwang, additional, Li, Yong, additional, Yan, Zhuchen, additional, Li, Jin, additional, Bai, Li-Yuan, additional, Chan, Catherine, additional, Yusuf, Akeem, additional, Zahlten-Kümeli, Anita, additional, Taylor, Kate, additional, and Yamaguchi, Kensei, additional

Published
2024
Full Text
View/download PDF

2. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Author

Qiu, Miao-Zhen, primary, Oh, Do-Youn, additional, Kato, Ken, additional, Arkenau, Tobias, additional, Tabernero, Josep, additional, Correa, Marcia Cruz, additional, Zimina, Anastasia V, additional, Bai, Yuxian, additional, Shi, Jianhua, additional, Lee, Keun-Wook, additional, Wang, Jufeng, additional, Poddubskaya, Elena, additional, Pan, Hongming, additional, Rha, Sun Young, additional, Zhang, Ruixing, additional, Hirano, Hidekazu, additional, Spigel, David, additional, Yamaguchi, Kensei, additional, Chao, Yee, additional, Wyrwicz, Lucjan, additional, Disel, Umut, additional, Cid, Roberto Pazo, additional, Fornaro, Lorenzo, additional, Evesque, Ludovic, additional, Wang, Hongwei, additional, Xu, Yaling, additional, Li, Jiang, additional, Sheng, Tao, additional, Yang, Silu, additional, Li, Liyun, additional, Moehler, Markus, additional, and Xu, Rui-Hua, additional

Published
2024
Full Text
View/download PDF

3. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Author

Shitara, Kohei, primary, Bang, Yung-Jue, additional, Iwasa, Satoru, additional, Sugimoto, Naotoshi, additional, Ryu, Min-Hee, additional, Sakai, Daisuke, additional, Chung, Hyun Cheol, additional, Kawakami, Hisato, additional, Yabusaki, Hiroshi, additional, Sakamoto, Yasuhiro, additional, Nishina, Tomohiro, additional, Inaki, Koichiro, additional, Kuwahara, Yusuke, additional, Wada, Naoya, additional, Suto, Fumitaka, additional, Arita, Takeo, additional, Sugihara, Masahiro, additional, Tsuchihashi, Zenta, additional, Saito, Kaku, additional, Kojima, Akihito, additional, and Yamaguchi, Kensei, additional

Published
2024
Full Text
View/download PDF

4. In vitro throughput screening of anticancer drugs using patient-derived cell lines cultured on vascularized three-dimensional stromal tissues

Author

Takahashi, Yuki, primary, Morimura, Rii, additional, Tsukamoto, Kei, additional, Gomi, Sayaka, additional, Kato, Asuka, additional, Mizukami, Miki, additional, Naito, Yasuyuki, additional, Irie, Shinji, additional, Nagayama, Satoshi, additional, Shinozaki, Eiji, additional, Yamaguchi, Kensei, additional, Fujita, Naoya, additional, Kitano, Shiro, additional, Katayama, Ryohei, additional, and Matsusaki, Michiya, additional

Published
2024
Full Text
View/download PDF

6. Pharmacological targeting of histone H3K27 acetylation/BRD4-dependent induction of ALDH1A3 for early-phase drug tolerance of gastric cancer

Author

Lee, Jin, primary, Mashima, Tetsuo, additional, Kawata, Naomi, additional, Yamamoto, Noriko, additional, Morino, Shun, additional, Inaba, Saori, additional, Nakamura, Ayane, additional, Kumagai, Koshi, additional, Wakatsuki, Takeru, additional, Takeuchi, Kengo, additional, Yamaguchi, Kensei, additional, and Seimiya, Hiroyuki, additional

Published
2024
Full Text
View/download PDF

7. Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

8. Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

9. Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

10. Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

11. Supplementary Table S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

12. Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

13. Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

14. Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

15. Supplementary Table S5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

16. Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

17. Supplementary Table S4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

18. Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

19. Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

20. Supplementary Table S4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

21. Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

22. Supplementary Table S5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

23. Supplementary Table S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

24. Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

25. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial

Author

Janjigian, Yelena Y., primary, Ajani, Jaffer A., additional, Moehler, Markus, additional, Shen, Lin, additional, Garrido, Marcelo, additional, Gallardo, Carlos, additional, Wyrwicz, Lucjan, additional, Yamaguchi, Kensei, additional, Cleary, James M., additional, Elimova, Elena, additional, Karamouzis, Michalis, additional, Bruges, Ricardo, additional, Skoczylas, Tomasz, additional, Bragagnoli, Arinilda, additional, Liu, Tianshi, additional, Tehfe, Mustapha, additional, Zander, Thomas, additional, Kowalyszyn, Ruben, additional, Pazo-Cid, Roberto, additional, Schenker, Michael, additional, Feeny, Kynan, additional, Wang, Rui, additional, Lei, Ming, additional, Chen, Clara, additional, Nathani, Raheel, additional, and Shitara, Kohei, additional

Published
2024
Full Text
View/download PDF

26. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

Author

Wainberg, Zev A., primary, Kang, Yoon-Koo, additional, Lee, Keun-Wook, additional, Qin, Shukui, additional, Yamaguchi, Kensei, additional, Kim, In-Ho, additional, Saeed, Anwaar, additional, Oh, Sang Cheul, additional, Li, Jin, additional, Turk, Haci Mehmet, additional, Teixeira, Alexandra, additional, Hitre, Erika, additional, Udrea, Adrian A., additional, Cardellino, Giovanni Gerardo, additional, Sanchez, Raquel Guardeño, additional, Zahlten-Kümeli, Anita, additional, Taylor, Kate, additional, and Enzinger, Peter C., additional

Published
2024
Full Text
View/download PDF

27. Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, additional, Sugimoto, Naotoshi, additional, Kawakami, Hisato, additional, Oshima, Takashi, additional, Yamaguchi, Kensei, additional, Hino, Kaori, additional, Hirao, Motohiro, additional, Kurokawa, Yukinori, additional, Kawakami, Takeshi, additional, Tsuda, Masahiro, additional, Hara, Hiroki, additional, Kaname, Shota, additional, Matsuoka, Daiko, additional, Otake, Yohei, additional, Yasuda, Keisuke, additional, Takase, Takao, additional, Takashima, Shuya, additional, Semba, Taro, additional, and Muro, Kei, additional

Published
2024
Full Text
View/download PDF

28. Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.

Author

Shah, Manish A., primary, Shitara, Kohei, additional, Lonardi, Sara, additional, Chao, Yee, additional, Yamaguchi, Kensei, additional, Kukielka-Budny, Bozena, additional, Ryu, Min-Hee, additional, Ungureanu, Andrei, additional, Oh, Mok, additional, Chang, Lawrence, additional, Yang, Hongbo, additional, Chai, Xinglei, additional, Bhattacharya, Pranob P., additional, Matsangou, Maria, additional, Ranganath, Radhika, additional, Ajani, Jaffer A., additional, and Xu, Rui-Hua, additional

Published
2024
Full Text
View/download PDF

29. Safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (Neo DCF) therapy for locally advanced esophageal cancer: Real world data analysis.

Author

Tamba, Mikako, primary, Osumi, Hiroki, additional, Fukuoka, Shota, additional, Ogura, Mariko, additional, Okamura, Akihiko, additional, Kanamori, Jun, additional, Imamura, Yu, additional, Takahari, Daisuke, additional, Yoshino, Koichiro, additional, Udagawa, Shohei, additional, Wakatsuki, Takeru, additional, Shinozaki, Eiji, additional, Watanabe, Masayuki, additional, Yamaguchi, Kensei, additional, Chin, Keisho, additional, and Ooki, Akira, additional

Published
2024
Full Text
View/download PDF

30. Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A single-institution retrospective study.

Author

Shimozaki, Keitaro, primary, Nakayama, Izuma, additional, Takahari, Daisuke, additional, Nagashima, Kengo, additional, Yoshino, Koichiro, additional, Fukuda, Koshiro, additional, Fukuoka, Shota, additional, Osumi, Hiroki, additional, Ogura, Mariko, additional, Wakatsuki, Takeru, additional, Ooki, Akira, additional, Shinozaki, Eiji, additional, Chin, Keisho, additional, and Yamaguchi, Kensei, additional

Published
2024
Full Text
View/download PDF

31. A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.

Author

Kotani, Daisuke, primary, Yamaguchi, Kensei, additional, Kato, Ken, additional, Hara, Hiroki, additional, Miura, Akinori, additional, Satoh, Taroh, additional, Komine, Keigo, additional, Kunisaki, Chikara, additional, Yabusaki, Hiroshi, additional, Hagiwara, Akiko, additional, Suzuki, Noriko, additional, Toyoizumi, Kiichiro, additional, Curtin, Joshua C, additional, Chowdhury, Sanjib, additional, Knoblauch, Roland Elmar, additional, and Doi, Toshihiko, additional

Published
2024
Full Text
View/download PDF

32. Clinical utility of upfront circulating tumor DNA (ctDNA) genotyping to guide first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): A GOZILA substudy.

Author

Aoki, Yu, primary, Nakamura, Yoshiaki, additional, Komatsu, Yoshito, additional, Taniguchi, Hiroya, additional, Sunakawa, Yu, additional, Shiozawa, Manabu, additional, Kitagawa, Chiyoe, additional, Ohta, Takashi, additional, Matsuhashi, Nobuhisa, additional, Yamazaki, Kentaro, additional, Boku, Shogen, additional, Takahashi, Naoki, additional, Esaki, Taito, additional, Kawakami, Hisato, additional, Kagawa, Yoshinori, additional, Nishina, Tomohiro, additional, Yamaguchi, Kensei, additional, Bando, Hideaki, additional, and Yoshino, Takayuki, additional

Published
2024
Full Text
View/download PDF

33. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.

Author

Shitara, Kohei, primary, Moehler, Markus H., additional, Ajani, Jaffer A., additional, Shen, Lin, additional, Garrido, Marcelo, additional, Gallardo, Carlos, additional, Wyrwicz, Lucjan S., additional, Yamaguchi, Kensei, additional, Cleary, James M., additional, Elimova, Elena, additional, Bruges Maya, Ricardo Elias, additional, Karamouzis, Michalis, additional, Skoczylas, Tomasz, additional, Bragagnoli, Arinilda, additional, Liu, Tianshu, additional, Tehfe, Mustapha, additional, Feeney, Kynan, additional, Wang, Rui, additional, Nathani, Raheel, additional, and Janjigian, Yelena Y., additional

Published
2024
Full Text
View/download PDF

34. Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.

Author

Udagawa, Shohei, primary, Osumi, Hiroki, additional, Ooki, Akira, additional, Wakatsuki, Takeru, additional, Fukuoka, Shota, additional, Yoshino, Koichiro, additional, Tamba, Mikako, additional, Ogura, Mariko, additional, Takahari, Daisuke, additional, Chin, Keisho, additional, Yamaguchi, Kensei, additional, and Shinozaki, Eiji, additional

Published
2024
Full Text
View/download PDF

35. Results from the phase 1b/2 SGNTUC-024 study: Assessment of tucatinib, trastuzumab, and FOLFOX for HER2+ GI cancers.

Author

Park, Haeseong, primary, Bekaii-Saab, Tanios S., additional, Kim, Sunnie S., additional, Pishvaian, Michael J., additional, Sunakawa, Yu, additional, Kamath, Suneel Deepak, additional, Kawazoe, Akihito, additional, Muro, Kei, additional, Zhen, David Bing, additional, Hirano, Hidekazu, additional, Maestas, Erika, additional, Grierson, Patrick, additional, Sugimoto, Naotoshi, additional, Yamaguchi, Kensei, additional, Ubowski, Michelle, additional, Tan, Qianwen, additional, Adelberg, David E., additional, and Strickler, John H, additional

Published
2024
Full Text
View/download PDF

36. In Vitro Throughput Screening of Anticancer Drugs Using Patient-Derived Cell Lines Cultured on Vascularized Three-Dimensional Stromal Tissues

Author

Takahashi, Yuki, primary, Morimura, Rii, additional, Tsukamoto, Kei, additional, Gomi, Sayaka, additional, Kato, Asuka, additional, Mizukami, Miki, additional, Naito, Yasuyuki, additional, Nagayama, Satoshi, additional, Shinozaki, Eiji, additional, Yamaguchi, Kensei, additional, Fujita, Naoya, additional, Kitano, Shiro, additional, Katayama, Ryohei, additional, and Matsusaki, Michiya, additional

Published
2024
Full Text
View/download PDF

37. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649

Author

Moehler, Markus, primary, Xiao, Hong, additional, Blum, Steven I., additional, Elimova, Elena, additional, Cella, David, additional, Shitara, Kohei, additional, Ajani, Jaffer A., additional, Janjigian, Yelena Y., additional, Garrido, Marcelo, additional, Shen, Lin, additional, Yamaguchi, Kensei, additional, Liu, Tianshu, additional, Schenker, Michael, additional, Kowalyszyn, Ruben, additional, Bragagnoli, Arinilda Campos, additional, Bruges, Ricardo, additional, Montesarchio, Vincenzo, additional, Pazo-Cid, Roberto, additional, Hunter, Shannon, additional, Davenport, Eric, additional, Wang, Jinyi, additional, Kondo, Kaoru, additional, Li, Mingshun, additional, and Wyrwicz, Lucjan, additional

Published
2023
Full Text
View/download PDF

38. Exploratory Analysis of Serum HER2 Extracellular Domain for HER2 Positive Gastric Cancer Treated with SOX plus Trastuzumab

Author

Wakatsuki, Takeru, primary, Ishizuka, Naoki, additional, Hironaka, Shuichi, additional, Minashi, Keiko, additional, Kadowaki, shigenori, additional, Goto, Masanori, additional, Shoji, Hirokazu, additional, Hirano, Hidekazu, additional, Nakayama, Izuma, additional, Osumi, Hiroki, additional, Ogura, Mariko, additional, Chin, Keisho, additional, Yamaguchi, Kensei, additional, and Takahari, Daisuke, additional

Published
2023
Full Text
View/download PDF

39. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells

Author

Chen, Mingjue, primary, Mashima, Tetsuo, additional, Oishi, Taichi, additional, Muramatsu, Yukiko, additional, Seto, Yosuke, additional, Takamatsu, Manabu, additional, Kawata, Naomi, additional, Morino, Shun, additional, Nakamura, Ayane, additional, Inaba, Saori, additional, Yuan, Xunmei, additional, Maruyama, Kohei, additional, Suzuki, Mai, additional, Sato, Ayana, additional, Yoshida, Haruka, additional, Jang, Myung-Kyu, additional, Mizutani, Anna, additional, Takeuchi, Kengo, additional, Yamaguchi, Kensei, additional, Shirai, Fumiyuki, additional, Nagayama, Satoshi, additional, Katayama, Ryohei, additional, and Seimiya, Hiroyuki, additional

Published
2023
Full Text
View/download PDF

40. Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study

Author

Shitara, Kohei, primary, Yamaguchi, Kensei, additional, Muro, Kei, additional, Yasui, Hisateru, additional, Sakai, Daisuke, additional, Oshima, Takashi, additional, Fujimura, Masahiro, additional, Sato, Yuta, additional, Yamazaki, Shunsuke, additional, Wakabayashi, Tatsuya, additional, Sugihara, Masahiro, additional, Kamio, Takahiro, additional, and Shoji, Hirokazu, additional

Published
2023
Full Text
View/download PDF

41. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Author

Rha, Sun Young, primary, Oh, Do-Youn, additional, Yañez, Patricio, additional, Bai, Yuxian, additional, Ryu, Min-Hee, additional, Lee, Jeeyun, additional, Rivera, Fernando, additional, Alves, Gustavo Vasconcelos, additional, Garrido, Marcelo, additional, Shiu, Kai-Keen, additional, Fernández, Manuel González, additional, Li, Jin, additional, Lowery, Maeve A, additional, Çil, Timuçin, additional, Cruz, Felipe Melo, additional, Qin, Shukui, additional, Luo, Suxia, additional, Pan, Hongming, additional, Wainberg, Zev A, additional, Yin, Lina, additional, Bordia, Sonal, additional, Bhagia, Pooja, additional, Wyrwicz, Lucjan S, additional, Mendez, Guillermo, additional, O'Connor, Juan Manuel, additional, Yanzi Castilla, Alvaro, additional, Cundom, Juan, additional, Kaen, Diego, additional, Wong, Rachel, additional, Ng, Weng, additional, Aghmesheh, Morteza, additional, Peressoni, Mauricio, additional, Andrade, Carlos, additional, Franke, Fabio, additional, Alves, Gustavo, additional, Cruz, Felipe Jose, additional, Vianna, Karina, additional, Monteiro, Maria Marcela, additional, Raphael, Michael, additional, Berry, Scott, additional, Jang, Raymond, additional, Tan, Ann, additional, Asselah, Jamil, additional, Yanez Weber, Patricio, additional, Mahave, Mauricio, additional, Sanchez, Cesar, additional, Salman, Pamela, additional, Zhang, Xiaochun, additional, Liu, Tianshu, additional, Lin, Xiaoyan, additional, Yang, Jianwei, additional, Li, Wei, additional, Ying, Jieer, additional, Chen, Xi, additional, Zeng, Shan, additional, Qu, Yanli, additional, Yang, Lin, additional, Zhao, Lin, additional, Chen, Ping, additional, Li, Enxiao, additional, Ye, Feng, additional, Lu, Jianwei, additional, Liang, Xinjun, additional, Zhao, Qun, additional, Yin, Xianli, additional, Li, Junhe, additional, Ling, Yang, additional, Lv, Guoqing, additional, Li, Shouguo, additional, Guerrero, Alvaro, additional, Rubiano, Juan, additional, Gonzalez Fernandez, Manuel, additional, Manneh Kopp, Ray, additional, Guzman Ramirez, Adrian, additional, Corrales, Luis, additional, Gonzalez Herrera, Ileana, additional, Melichar, Bohuslav, additional, Buchler, Tomas, additional, Svoboda, Tomas, additional, Obermannova, Radka, additional, Vrana, David, additional, Cvek, Jakub, additional, Pfeiffer, Per, additional, Baeksgaard, Lene, additional, Yilmaz, Mette, additional, Boige, Valerie, additional, Lopez-Trabada, Daniel, additional, Borg, Christophe, additional, Pannier, Diane, additional, Hiret, Sandrine, additional, Di Fiore, Frederic, additional, Metges, Jean-Philippe, additional, Arnold, Dirk, additional, Martens, Uwe, additional, Lordick, Florian, additional, Stein, Alexander, additional, Castro, Hugo, additional, Lopez, Karla, additional, Ramirez, Julio, additional, Aguilar, Mynor, additional, Chivalan, Marco, additional, Chan, Wendy, additional, Cheng, Ashley, additional, Yeo, Winnie, additional, Arkosy, Peter, additional, Csoszi, Tibor, additional, Hitre, Erika, additional, Horvath, Zsolt, additional, Lowery, Maeve, additional, McDermott, Ray, additional, Morris, Patrick, additional, Hubert, Ayala, additional, Brenner, Baruch, additional, Ben-Aharon, Irit, additional, Shacham-Shmueli, Einat, additional, Man, Sofia, additional, Pelles Avraham, Sharon, additional, Brenner, Ronen, additional, Mishaeli, Moshe, additional, Di Bartolomeo, Maria, additional, Fazio, Nicola, additional, Lonardi, Sara, additional, Garufi, Carlo, additional, Satoh, Taroh, additional, Hara, Hiroki, additional, Iwagami, Shiro, additional, Yasui, Hisateru, additional, Tsuda, Masahiro, additional, Shimoyama, Tatsu, additional, Shoji, Hirokazu, additional, Sugimoto, Naotoshi, additional, Shibata, Nobuhiro, additional, Yamaguchi, Kensei, additional, Amagai, Kenji, additional, Choda, Yasuhiro, additional, Esaki, Taito, additional, Yabusaki, Hiroshi, additional, Oshima, Takashi, additional, Tsuji, Akihito, additional, Kawakami, Hisato, additional, Kawazoe, Akihito, additional, Ishido, Kenji, additional, Kadowaki, Shigenori, additional, Martinez Rodriguez, Jorge, additional, Herrera Martinez, Marytere, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Balancan, Paola, additional, Damianovich, Dragan, additional, Castro Oliden, Victor, additional, Grados, Julio, additional, Torres, Cesar, additional, Wyrwicz, Lucjan, additional, Wysocki, Piotr, additional, Hajac, Lukasz, additional, Zolnierek, Jakub, additional, Karaszewska, Boguslawa, additional, Rha, Sun Young, additional, Orlova, Rashida, additional, Tjulandin, Sergey, additional, Fadeeva, Natalia, additional, Makarycheva, Yulia, additional, Nosov, Dmitry, additional, Smagina, Maria, additional, Chan, Sze, additional, Jacobs, Conrad, additional, Kraus, Peter, additional, Landers, Gregory, additional, Robertson, Barbara, additional, Ruff, Paul, additional, Schoeman, Elizabeth, additional, Maurel, Jean-Marc, additional, Diez Garcia, Marc, additional, Jimenez Fonseca, Paula, additional, Gallego Plazas, Javier, additional, Rivera Herrero, Fernando, additional, Miranda Poma, Jesus, additional, Layos Romero, Laura, additional, Fritsch, Ralph, additional, Bastian, Sara, additional, Winterhalder, Ralph, additional, Dosso, Sara De, additional, Kossler, Thibaud, additional, Yeh, Kun-Huei, additional, Yen, Chia-Jui, additional, Chen, Yen-Yang, additional, Lin, Johnson, additional, Bilici, Mehmet, additional, Ozguroglu, Mustafa, additional, Cil, Timucin, additional, Oksuzoglu, Berna, additional, Harputluoglu, Hakan, additional, Karaoglu, Aziz, additional, Hacibekiroglu, Ilhan, additional, Erdogan, Bulent, additional, Yalcin, Suayib, additional, Adamchuk, Hryhoriy, additional, Bondarenko, Igor, additional, Kolesnik, Oleksii, additional, Ostapenko, Yuriy, additional, Kryzhanivska, Anna, additional, Leshchenko, Lurii, additional, Ilin, Ievgen, additional, Shparyk, Yaroslav, additional, Trukhin, Dmytro, additional, Voitko, Nataliia, additional, Roy, Rajarshi, additional, Young, Anna-Mary, additional, Medley, Louise, additional, Celano, Paul, additional, Overton, Lindsay, additional, Raj, Moses, additional, Dunne, Richard, additional, Wainberg, Zev, additional, Dayyani, Farshid, additional, Larson, Timothy, additional, and Kochenderfer, Mark, additional

Published
2023
Full Text
View/download PDF

42. MO39-1 CapeOX therapy for elderly pts with advanced gastric cancer (phase II study with geriatric assessment, TCOG GI-1601)

Author

Muto, Osamu, primary, Chin, Keisho, additional, Kawabata, Ryohei, additional, Hosaka, Hisashi, additional, Shindo, Yoshiaki, additional, Nagata, Naoki, additional, Yabusaki, Hiroshi, additional, Kawase, Tomono, additional, Endo, Shunji, additional, Kashiwada, Tomomi, additional, Nakamura, Masato, additional, Hihara, Jun, additional, Kobayashi, Michiya, additional, Nagashima, Fumio, additional, Takahari, Daisuke, additional, Ishizuka, Naoki, additional, and Yamaguchi, Kensei, additional

Published
2023
Full Text
View/download PDF

43. MO39-4 Efficacy and safety of trifluridine/tipiracil as a salvage-line treatment for patients with advanced gastric cancer

Author

Fukuda, Koshiro, primary, Takahari, Daisuke, additional, Osumi, Hiroki, additional, Nakayama, Izuma, additional, Fukuoka, Shota, additional, Ogura, Mariko, additional, Ooki, Akira, additional, Wakatsuki, Takeru, additional, Shimozaki, Keitaro, additional, Yoshino, Koichiro, additional, Shinozaki, Eiji, additional, Chin, Keisho, additional, and Yamaguchi, Kensei, additional

Published
2023
Full Text
View/download PDF

44. Cetuximab every 2 weeks versus standard weekly dosing administration schedule

Author

Bokemeyer, Carsten, primary, Ciardiello, Fortunato, additional, Dubreuil, Olivier, additional, Guigay, Joel, additional, Kasper, Stefan, additional, Pfeiffer, Per, additional, Pinto, Carmine, additional, Yamaguchi, Kensei, additional, Yoshino, Takayuki, additional, Zielinski, Christoph, additional, Esser, Regina, additional, and Tabernero, Josep, additional

Published
2023
Full Text
View/download PDF

45. Neoadjuvant chemotherapy for borderline resectable colorectal cancer liver metastases: A single-institution retrospective study

Author

Kitano, Yuki, primary, Ono, Yoshihiro, additional, Kobayashi, Kosuke, additional, Oba, Atsushi, additional, Sato, Takafumi, additional, Ito, Hiromichi, additional, Inoue, Yosuke, additional, Shinozaki, Eiji, additional, Yamaguchi, Kensei, additional, Saiura, Akio, additional, Baba, Hideo, additional, and Takahashi, Yu, additional

Published
2023
Full Text
View/download PDF

46. A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer

Author

Osumi, Hiroki, primary, Takashima, Atsuo, additional, Ooki, Akira, additional, Yoshinari, Yuri, additional, Wakatsuki, Takeru, additional, Hirano, Hidekazu, additional, Nakayama, Izuma, additional, Okita, Natsuko, additional, Sawada, Ryoichi, additional, Ouchi, Kota, additional, Fukuda, Koshiro, additional, Fukuoka, Shota, additional, Ogura, Mariko, additional, Takahari, Daisuke, additional, Chin, Keisho, additional, Shoji, Hirokazu, additional, Kato, Ken, additional, Ishizuka, Naoki, additional, Boku, Narikazu, additional, Yamaguchi, Kensei, additional, and Shinozaki, Eiji, additional

Published
2023
Full Text
View/download PDF

47. Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study

Author

Kawabata, Ryohei, primary, Chin, Keisho, additional, Takahari, Daisuke, additional, Hosaka, Hisashi, additional, Muto, Osamu, additional, Shindo, Yoshiaki, additional, Nagata, Naoki, additional, Yabusaki, Hiroshi, additional, Imamura, Hiroshi, additional, Endo, Shunji, additional, Kashiwada, Tomomi, additional, Nakamura, Masato, additional, Hihara, Jun, additional, Kobayashi, Michiya, additional, Sagawa, Tamotsu, additional, Saito, Soh, additional, Sato, Atsushi, additional, Yamada, Takeshi, additional, Okano, Naohiro, additional, Shimada, Ken, additional, Matsushima, Masashi, additional, Kataoka, Masato, additional, Matsumoto, Shigemi, additional, Goto, Masahiro, additional, Kotaka, Masahito, additional, Shiraishi, Takeshi, additional, Yamai, Hiromichi, additional, Nagashima, Fumio, additional, Ishizuka, Naoki, additional, and Yamaguchi, Kensei, additional

Published
2023
Full Text
View/download PDF

48. ASO Visual Abstract: Prognostic Impact of Tumor Markers (CEA and CA19-9) in Patients with Resectable Colorectal Liver Metastases Stratified by Tumor Number and Size: Potentially Valuable Biological Markers for Preoperative Treatment

Author

Kobayashi, Kosuke, primary, Ono, Yoshihiro, additional, Kitano, Yuki, additional, Oba, Atsushi, additional, Sato, Takafumi, additional, Ito, Hiromichi, additional, Mise, Yoshihiro, additional, Shinozaki, Eiji, additional, Inoue, Yosuke, additional, Yamaguchi, Kensei, additional, Saiura, Akio, additional, and Takahashi, Yu, additional

Published
2023
Full Text
View/download PDF

50. Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors

Author

Fukuda, Koshiro, primary, Osumi, Hiroki, additional, Yoshino, Koichiro, additional, Nakayama, Izuma, additional, Fukuoka, Shota, additional, Ogura, Mariko, additional, Wakatsuki, Takeru, additional, Ooki, Akira, additional, Takahari, Daisuke, additional, Chin, Keisho, additional, Yamaguchi, Kensei, additional, and Shinozaki, Eiji, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results